ArticleMedicine2026
A hemodialysis patient with recurrent Wernicke encephalopathy showed reversible lentiform fork sign: A case report.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleThis case report describes an unusual presentation of recurrent Wernicke encephalopathy (WE) in a patient undergoing hemodialysis, with distinctive neuroimaging findings that provide new insights into the disease. PATIENT CONCERNS: The patient presented with progressive gait ataxia, dysarthria, and mild memory impairment, with recurrent neurological symptoms following thiamin discontinuation. DIAGNOSES: WE was diagnosed based on characteristic MRI findings including the rare lentiform fork sign and other atypical brain lesions, supported by symptom recurrence after thiamin cessation and radiological reversibility with treatment.
interventionsThe patient received immediate thiamin supplementation therapy, close neurological monitoring, and regular hemodialysis. OUTCOMES: Neurological symptoms significantly improved with treatment, and MRI showed reversal of the lentiform fork sign and other atypical lesions, demonstrating the importance of sustained thiamin management during follow-up. LESSONS: This case highlights the lentiform fork sign as a valuable neuroimaging marker for WE, suggests that blood-brain barrier dysfunction may be pathogenic, and emphasizes the need for continuous thiamin management in high-risk patients to prevent recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.